Generic Name: bicalutamide

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: Yes

Experimental Code: N/A

Drug Indication

Casodex is an androgen receptor inhibitor approved for metastatic prostate cancer.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Medical or surgical castration reduces testosterone levels, but other cells in the body can still make androgens. Medications like Casodex bind to androgen receptors in prostate cells and prevent them from sending chemical signals that trigger cancer cell proliferation. They are usually combined with GnRH agonists to stop testosterone production, known as androgen deprivation therapy (ADT).

Dosage

Dosing Info: Casodex is taken as a once-daily pill.

Side Effects

Common side effects include hot flashes, pain, weakness, constipation, diarrhea, nausea, swelling and nighttime urination. Casodex may cause breast pain and enlargement (gynecomastia). Potential serious side effects include liver toxicity and a higher risk of diabetes.

For More Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/076932s000lbl.pdf

Co-Pay Program Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/076932s000lbl.pdf

Patient Assistance Program Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/076932s000lbl.pdf

Last Reviewed: September 19, 2018